---
title: "Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281008093.md"
description: "Cytosorbents reported fiscal 2025 revenue of $37.1 million, a 4.1% increase from 2024, with a narrowed net loss of $8.2 million compared to $20.7 million the previous year. Gross profit rose to $26.5 million, achieving a 71.5% margin. The company is focusing on cost reductions and operational realignment to reach cash-flow break-even by the second half of 2026. Key initiatives include a 10% workforce reduction and a strategic shift in its German commercial team to enhance sales performance."
datetime: "2026-03-30T11:15:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281008093.md)
  - [en](https://longbridge.com/en/news/281008093.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281008093.md)
---

# Cytosorbents 10-K: Revenue $37.1M, EPS not disclosed

Cytosorbents reported fiscal 2025 revenue of $37.1 million and a narrowed net loss of $8.2 million versus a $20.7 million loss in 2024; earnings per share were not disclosed in the filing. Gross profit improved to $26.5 million with a 71.5% margin, while loss from operations improved to $(14.7) million. The company is prioritizing cost reductions and operational realignment to target cash-flow break-even in the second half of 2026.

**Financial Highlights**

-   **Revenue:** $37.1 million, an increase of 4.1% versus 2024 (down 0.4% on a constant currency basis).
-   **Gross Profit:** $26.5 million; gross margin 71.5% versus 69.9% in the prior year.
-   **Operating Income:** Loss from operations of $(14.7) million, improved 10.4% from $(16.5) million.
-   **Net Income:** Net loss of $(8.2) million, improved from a net loss of $(20.7) million in 2024.
-   **Net Income Per Share:** Not provided in Part II Item 7/Item 8 of the filing.

**Business Highlights**

-   **Revenue drivers:** Product revenue growth was driven by distributor and partner sales and direct sales outside Germany.
-   **Market & channel actions:** The company reorganized its German commercial team following weaker direct sales in Germany and expects stronger execution from this change.
-   **Clinical and brand momentum:** More than 300,000 CytoSorb devices have been used globally; new clinical data presented at major conferences indicate improved outcomes in cardiac surgery and sepsis.
-   **Operational efficiency initiatives:** Implemented a Strategic Workforce & Cost Reduction Plan, reducing headcount by approximately 10% and realigning costs to pursue cash-flow break-even in H2 2026.
-   **R&D and regulatory focus:** R&D spending was reduced by about 33% following completion of the STAR-T trial; the company is preparing a resubmission for FDA De Novo for DrugSorb-ATR and engaging in ongoing pre-submission discussions.

Original SEC Filing: Cytosorbents Corp \[ CTSO \] - 10-K - Mar. 30, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CTSO.US](https://longbridge.com/en/quote/CTSO.US.md)

## Related News & Research

- [CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update | CTSO Stock News](https://longbridge.com/en/news/286308377.md)
- [Forum Markets GAAP EPS of $0.06 beats by $0.28, revenue of $2.9M beats by $1.5M](https://longbridge.com/en/news/286415134.md)
- [Regeneron Sinks 10% on Failed Phase 3 Melanoma Trial. What Comes Next for REGN Stock.](https://longbridge.com/en/news/286811938.md)
- [How Chubb’s (CB) New Canada Cancer Coverage Launch Could Reframe Its Health Benefits Strategy](https://longbridge.com/en/news/286787301.md)
- [Alpha Tau Q1 Net Loss Expands; Plans Enrollment Completion In IMPACT Study In Q3,2026; Stock Up](https://longbridge.com/en/news/286879279.md)